According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially serious toxicities that should be closely monitored.
Laurence Albiges, MD, PhD
Advertisement
Articles by Laurence Albiges, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Oncology Nursing News
1
An NP’s Perspective: Supporting Derm Toxicities in Breast Cancer as a Team
2
NGS Streamlines Biomarker Testing in Solid Tumors
3
Solo Sevabertinib Shows Durable Activity in HER2+ NSCLC
4
Managing Acute and Late Adverse Effects of Breast Cancer Radiation
5
